آوانافیل (Persian Wikipedia)

Analysis of information sources in references of the Wikipedia article "آوانافیل" in Persian language version.

refsWebsite

Global rank Persian rank

4^th place

5^th place

2^nd place

1^st place

low place

6^th place

9^th place

11^th place

52^nd place

3,984^th place

1,143^rd place

3,840^th place

1,585^th place

archive.org

Kyle JA, Brown DA, Hill JK (October 2013). "Avanafil for erectile dysfunction". The Annals of Pharmacotherapy. Sage Publishing. 47 (10): 1312–1320. doi:10.1177/1060028013501989. PMID 24259695. S2CID 6562049.
Kotera J, Mochida H, Inoue H, Noto T, Fujishige K, Sasaki T, et al. (August 2012). "Avanafil, a potent and highly selective phosphodiesterase-5 inhibitor for erectile dysfunction". The Journal of Urology. 188 (2): 668–674. doi:10.1016/j.juro.2012.03.115. PMID 22704456.

Burke RM, Evans JD (2012). "Avanafil for treatment of erectile dysfunction: review of its potential". Vascular Health and Risk Management. 8: 517–523. doi:10.2147/VHRM.S26712. PMC 3433322. PMID 22973106.
Kyle JA, Brown DA, Hill JK (October 2013). "Avanafil for erectile dysfunction". The Annals of Pharmacotherapy. Sage Publishing. 47 (10): 1312–1320. doi:10.1177/1060028013501989. PMID 24259695. S2CID 6562049.
Kotera J, Mochida H, Inoue H, Noto T, Fujishige K, Sasaki T, et al. (August 2012). "Avanafil, a potent and highly selective phosphodiesterase-5 inhibitor for erectile dysfunction". The Journal of Urology. 188 (2): 668–674. doi:10.1016/j.juro.2012.03.115. PMID 22704456.
Sanford M (October 2013). "Avanafil: A Review of Its Use in Patients with Erectile Dysfunction". Drugs & Aging. 30 (10): 853–62. doi:10.1007/s40266-013-0112-x. PMID 23955441. S2CID 23558269.

Burke RM, Evans JD (2012). "Avanafil for treatment of erectile dysfunction: review of its potential". Vascular Health and Risk Management. 8: 517–523. doi:10.2147/VHRM.S26712. PMC 3433322. PMID 22973106.
Kyle JA, Brown DA, Hill JK (October 2013). "Avanafil for erectile dysfunction". The Annals of Pharmacotherapy. Sage Publishing. 47 (10): 1312–1320. doi:10.1177/1060028013501989. PMID 24259695. S2CID 6562049.
Kotera J, Mochida H, Inoue H, Noto T, Fujishige K, Sasaki T, et al. (August 2012). "Avanafil, a potent and highly selective phosphodiesterase-5 inhibitor for erectile dysfunction". The Journal of Urology. 188 (2): 668–674. doi:10.1016/j.juro.2012.03.115. PMID 22704456.
Sanford M (October 2013). "Avanafil: A Review of Its Use in Patients with Erectile Dysfunction". Drugs & Aging. 30 (10): 853–62. doi:10.1007/s40266-013-0112-x. PMID 23955441. S2CID 23558269.

Kyle JA, Brown DA, Hill JK (October 2013). "Avanafil for erectile dysfunction". The Annals of Pharmacotherapy. Sage Publishing. 47 (10): 1312–1320. doi:10.1177/1060028013501989. PMID 24259695. S2CID 6562049.
Sanford M (October 2013). "Avanafil: A Review of Its Use in Patients with Erectile Dysfunction". Drugs & Aging. 30 (10): 853–62. doi:10.1007/s40266-013-0112-x. PMID 23955441. S2CID 23558269.

"Prescription medicines: registration of new chemical entities in Australia, 2016". Therapeutic Goods Administration (TGA). 21 June 2022. Archived from the original on 10 April 2023. Retrieved 10 April 2023.